InMed Pharmaceuticals

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer’s Disease Program. See full press release: ow.ly/J5tx50Yxo1u

InMed's President and CEO, Eric A. Adams, presents at Renmark Financial's Virtual Non-Deal Roadshow on February 26, 2026. In the presentation and Q&A, Mr. Adams gives an overview of the company's pharmaceutical programs, including lead drug candidate INM-901 for Alzheimer's disease, and answers these questions: -How soon do you expect to start INM-901 Phase 1 clinical trial enrollment following a successful IND application? -Will a Phase 1 clinical trial of INM-901 be conducted in healthy volunteers or in patients living with Alzheimer's disease? -As INM-901 moves into the clinical development phase, do you expect to increase headcount or will this be outsourced? -While you've had promising preclinical data of INM-901 so far, what gives you the confidence INM-901's preclinical results will translate similarly into human clinical trials? Watch the presentation and Q&A here: ow.ly/aQ8f50Ys1V7 $INM #Alzheimers #pharma #neuroinflammation @RenmarkMedia

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial “Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027." ~Eric A. Adams, CEO Read news release: ow.ly/QYP850YrmFc $INM #alzheimers #pharma

#News: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial "We further refined the program’s direction and reinforced our conviction that targeting neuroinflammation is critical to addressing Alzheimer’s disease progression.” Read news release: ow.ly/nbum50YrnaS $INM #AlzheimersDisease #Alzheimers #neuroinflammation #pharma

#NEWS: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial -Advancing Alzheimer’s and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities -Targeting Initiation of Phase 1 Clinical Trial in Alzheimer’s Disease in 2027 Read news release: ow.ly/Rqrj50Yrmev $INM #Alzheimers #DryAMD #AlzheimersDisease #pharma

InMed's CEO, Eric A. Adams, presents at the @RenmarkMedia Non-Deal Roadshow. Eric presents the preclinical studies that demonstrate how INM-901 reduces neuroinflammation associated with Alzheimer's disease. He also talks about the role of CB1 and CB2 receptors in neuroinflammation. Watch here: renmark-drupal.s3.amazonaws.com/vndr/inmed-pha… $INM #Alzheimers #AlzheimersDisease #research #neuroinflammation #inflammation

-How is InMed's INM-901 different from other Alzheimer’s therapeutics? In this presentation, Mr. Adams speaks about how INM-901 targets the reduction of neuroinflammation. Neuroinflammation is now recognized as a key driver of Alzheimer’s disease development and progression. Mr. Adams also speaks about the upcoming development plans for INM-901 including its preparation for a pre-IND meeting with the FDA. Watch video here: ow.ly/7Jbx50YkzMa $INM #Alzheimers #neuroinflammation #preclinical #AlzheimersResearch #Pharma #Biotech #AlzheimersStudy

InMed today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025. During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program. Full news release: ow.ly/R2nA50Ye8EY $INM #Alzheimers #study #pharma #neuroinflammation

#NEWS InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update “We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities.” ~ Eric A. Adams, CEO Read full news release here: ow.ly/pfHo50Ye8Bz $INM #Alzheimers #pipeline #pharma

#News: InMed Announces Results of 2025 Annual General and Special Meeting Read news release here: ow.ly/KVZ050XLfuQ $INM

InMed presents at the Life Sciences Virtual Investor Forum. CEO Eric A. Adams gives a company update and shares the preclinical data on InMed's lead compound INM-901 for #Alzheimers disease. Presentation available on demand here: ow.ly/8mPp50XICfX $INM #lifesciences #pharma

What is the role of neuroinflammation in Alzheimer's disease development and progression? This panel of #Alzheimers disease experts talk about what to expect in Alzheimer's research in the next few years and why #neuroinflammation is an important target for novel Alzheimer's treatments. Discussion here: ow.ly/XXir50XC36E $INM #research #biotech #pharma #inflammation #AlzheimersDisease

Summary of InMed's INM-901 Pharmacokinetics Study: -Over a seven-day dosing period, study demonstrated robust bioavailability with INM-901 achieving what is anticipated to be therapeutic levels of systemic exposure -Neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects -InMed has completed additional CMC development to scale manufacturing in preparation for pre-IND meeting with FDA More here: ow.ly/a4hY50XAhoW $INM #Alzheimers #PKStudies

Video Replay on Demand: InMed Presents at the Life Sciences Investor Forum. InMed's CEO Eric A. Adams gives a progress update on InMed’s pipeline including recent data from the Company’s leading pharmaceutical program INM-901 in the treatment of Alzheimer’s disease. The new preclinical data was recently presented at the Alzheimer’s Association International Conference (AAIC) 2025, the world’s leading forum for Alzheimer’s disease and dementia research. inmedpharma.com/learn/inmed-pr… $INM #Alzheimers #pipeline #INM901 #preclinical #pharma

What is neuritogenesis? In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning. Video here: inmedpharma.com/learn/what-is-… $INM #neuritogenesis #Alzheimers #amyloidbeta #neurites

InMed has conducted several in vitro and in vivo studies to test the pharmacological effects of INM-901 in Alzheimer’s disease preclinical models with promising results demonstrating disease-modifying effects. A summary of INM-901 preclinical study results: ➡️ Demonstrates neuroprotective effects by reducing cell death in an amyloid-beta-induced cytotoxicity study ➡️ Demonstrates significant reduction in inflammatory biomarkers associated with Alzheimer’s, including IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2 & NfL ➡️ May have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation ➡️ Demonstrates an ability to promote neurite outgrowth, signifying the potential to improve neuronal function, a potential breakthrough in the treatment of Alzheimer’s disease ➡️ Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior, sound awareness and neuronal function ➡️ Demonstrates robust bioavailability in in vivo models, achieving what is anticipated to be therapeutic levels of systemic exposure ➡️ Additional mRNA data supports the observations made in behavior studies in locomotor activity, cognition and memory. More about InMed's INM-901 program here: inmedpharma.com/pharmaceutical… $INM #Alzheimers #research #neuroprotection #neuroinflammation #pharma #biotech #studies

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step Alzheimer’s disease research experts come together for this informative session. Learn about: -Role of neuroinflammation in the development of cognition-impairing disease -Biological pathways to developing drugs to address neuroinflammation -Why neuroinflammation is an important target for novel Alzheimer’s treatments -Importance of patient diversity in clinical trial design -Scanning the horizon – what to expect in the next 5 years Watch Fierce Biotech webinar here: ow.ly/zqmv50XurIR $INM #Alzheimers #research #experts #neuroinflammation #inflammation #pharma #biotech

Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk Several studies presented at the AAIC 2025 conference investigated the correlation between inflammatory biomarkers and the risk of Alzheimer’s disease and other dementias. Researchers are turning their attention to how inflammation influences cognitive decline. Article here: ow.ly/RH0O50XtJka $INM #Alzheimers #pathology #neuroinflammation

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901. This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program. Read news release: ow.ly/3QBu50XtJqB $INM #Alzheimers #pharmacokinetics #PK #pharma #biotech

#NEWS: InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for its Alzheimer’s Disease Candidate INM-901 Read full news release here: ow.ly/aCUI50XteSx $INM #Alzheimers #Study #biotech #pharma #preclinical